LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
LFCR currently has 34.8M outstanding shares. with limited dilution risk as only 1.61M additional shares (4.6%) are authorized for issuance. The company has diluted shareholders by 22.03% over the past 2 years through share issuances.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Aug 07, 2025 |
10-K filing | 34.8M shares outstanding |
35M | 1.6M |
| Apr 03, 2025 |
10-Q filing | 37.0M shares outstanding |
37M | 0 |
| Jan 02, 2025 |
10-Q filing | 34.4M shares outstanding |
34M | 2.1M |
| Oct 10, 2024 |
POS AM filing: Lifecore Biomedical, Inc. is offering up to 12,667,486 shares of common stock by the Selling Stockholders. |
30M | 6M |
| Oct 10, 2024 |
S-1 filing: Lifecore Biomedical, Inc. is offering up to 6,795,344 shares of common stock by the Selling Stockholders. |
30M | 6M |
| Oct 04, 2024 |
10-Q filing | 30.9M shares outstanding |
31M | 11M |
| Oct 04, 2024 |
8-K filing: Lifecore Biomedical, Inc. sold 5,928,775 shares of its common stock at $4.10 per share for aggregate gross proceeds of approximately $24.3 million in a private placement that closed on October 3, 2024. ($24.3M proceeds) |
30M | 12M |
| Aug 26, 2024 |
10-K filing | 30.5M shares outstanding |
30M | 12M |
| Aug 09, 2024 |
10-Q filing | 30.5M shares outstanding |
30M | 12M |
| Aug 09, 2024 |
10-Q filing | 30.5M shares outstanding |
30M | 12M |
| Aug 09, 2024 |
10-Q filing | 30.4M shares outstanding |
30M | 12M |
| Mar 20, 2024 |
10-K filing | 30.0M shares outstanding |
30M | 12M |
| Jun 06, 2023 |
S-1/A filing: Lifecore Biomedical, Inc. is offering up to 12,667,486 shares of common stock by the Selling Stockholders. |
30M | 12M |
| Jun 02, 2023 |
10-Q filing | 30.3M shares outstanding |
30M | 12M |
| Apr 06, 2023 |
S-1 filing: Lifecore Biomedical, Inc. is offering up to 12,667,486 shares of common stock by the Selling Stockholders. |
30M | 13M |
| Mar 16, 2023 |
10-Q filing | 29.6M shares outstanding |
30M | 0 |
| Jan 10, 2023 |
8-K filing: Lifecore Biomedical, Inc. issued and sold 38,750 shares of Series A Convertible Preferred Stock for $38.75 million and amended its credit agreements with Goldman Sachs and BMO Harris Bank. ($38.75M proceeds) |
30M | 0 |
| Nov 25, 2022 |
8-K filing: Lifecore Biomedical, Inc. sold 627,746 shares of its common stock to entities affiliated with Wynnefield Capital, Inc. for gross proceeds of approximately $5.0 million at a price of $7.97 per share in a private placement that closed on November 25, 2022. ($5.0M proceeds) |
30M | 0 |
| Oct 07, 2022 |
10-Q filing | 29.6M shares outstanding |
30M | 0 |
| Sep 14, 2022 |
10-K filing | 29.5M shares outstanding |
29M | 0 |
| Apr 07, 2022 |
10-Q filing | 29.5M shares outstanding |
29M | 0 |
| Jan 07, 2022 |
10-Q filing | 29.5M shares outstanding |
29M | 0 |
| Oct 05, 2021 |
10-Q filing | 29.4M shares outstanding |
29M | 0 |
| Jul 29, 2021 |
10-K filing | 29.3M shares outstanding |
29M | 0 |
| Apr 08, 2021 |
10-Q filing | 29.3M shares outstanding |
29M | 0 |
| Jan 07, 2021 |
10-Q filing | 29.3M shares outstanding |
29M | 0 |
| Oct 07, 2020 |
10-Q filing | 29.2M shares outstanding |
29M | 0 |
| Aug 14, 2020 |
10-K filing | 29.2M shares outstanding |
29M | 0 |
| Apr 03, 2020 |
10-Q filing | 29.2M shares outstanding |
29M | 0 |
| Jan 02, 2020 |
10-Q filing | 27.8M shares outstanding |
28M | 0 |